Official prostate pointers.

In case you still haven’t heard, the addition of either docetaxel or abiraterone to androgen deprivation therapy (ADT) improves overall survival in men with metastatic castration sensitive prostate cancer (mCSPC). For those who don’t believe it until it’s written as guideline, ASCO has you covered. Finally. These lines guide you to consider using these therapies in all men with mCSPC, but you’re flat out wrong if you fail to offer docetaxel to men with high-volume disease as defined by CHAARTED and/or abiraterone to men with high-risk disease as defined by LATITUDE (at least 2 of the following: Gleason score ≥8, ≥3 bone mets, measurable visceral mets). It also includes a bonus dosing refresher: docetaxel 75 mg/m2 q3 weeks x 6 cycles +/- prednisolone 5 mg daily (extrapolated from STAMPEDE) and abiraterone at the full 1000 mg with prednisolone (per STAMPEDE) or prednisone (per LATITUDE) 5 mg daily. TBL: It’s official. Talk about the addition of abiraterone or docetaxel to ADT with all patients with mCSPC, especially those with high-volume and/or high-risk disease. | Morris, J Clin Oncol 2018